Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MHLW Grants NHI Listing To 23 Generic Makers For Daiichi Sankyo’s Levofloxacin

This article was originally published in PharmAsia News

Executive Summary

The Ministry of Health, Labor and Welfare May 15 listed 318 generic drugs for the national health insurance price listing, including 23 companies listed for Daiichi Sankyo's antibacterial Cravit (levofloxacin). Those generic companies include Sawai Pharmaceutical, Nichi-Iko, Taiyo and Towa Pharmaceutical. The NHI also included 39 generic drugs for Daiichi Sankyo's hypertension drug Acecol (temocapril). Japan's major generic drug makers such as Sawai had 22 drugs listed, Nichi-Iko had 23 drugs, Taiyo had 17, Nipro Pharma had 15 and Towa got 14 drugs listed. The generic drug NHI price listing is conducted twice a year in Japan, in July and November. The July date this year was moved up to May. (Click here for more - Japanese language

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

UsernamePublicRestriction

Register

SC071709

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel